Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

• DOI: 10.1136/rmdopen-2021-001814
• Publication Date: 2021-09-07T15:55:24Z
• Authors: Sebastian Eduardo...; Jean W Liew; Kevin Kennedy; Emily Sirotich; Michael Putman; Tarin T Moni; Akpabio Akpabio; Deshiré Alpízar-R...; Francis Berenbaum; Inita Bulina; Richard Conway; Aman Dev Singh; Eimear Duff; Karen L Durrant; Tamer A Gheita; Catherine L Hill; Richard A Howard; Bimba F Hoyer; Evelyn Hsieh; Lina El Kibbi; Adam Kilian; Alfred Hyoungju Kim; David F L Liew; Chieh Lo; Bruce Miller; Serena Mingolla; Michal Nudel; Candace A Palmerlee; Jasvinder A Singh; Namrata Singh; Manuel Francisco ...; John Wallace; Kristen J Young; Suleman Bhana; Wendy Costello; Rebecca Grainger; Pedro M Machado; Philip C Robinson; Paul Sufka; Zachary S Wallace; Jinoos Yazdany; Carly Harrison; Maggie Larché; Mitchell Levine; Gary Foster; Lehana Thabane; Lisa G Rider; Jonathan S Hausmann; Julia F Simard; Jeffrey A Sparks
• Keywords: Adult; Male; Aging; COVID-19 Vaccines; Coronaviruses; Clinical Sciences; 610; Coronaviruses Vaccines; Clinical sciences; Infections; Autoimmune Disease; Vaccine Related; 03 medical and health sciences; 0302 clinical medicine; Rheumatology; Rheumatic Diseases; Surveys and Questionnaires; 616; Humans; autoimmune diseases; Biomedical and Clinical Sciences; SARS-CoV-2; Arthritis; Prevention; Inflammatory and immune system; Vaccination; R; COVID-19; Middle Aged; vaccination; 3. Good health; Good Health and Well Being; Infectious Diseases; Emerging Infectious Diseases; 3.4 Vaccines; 6.1 Pharmaceuticals; Women's Health; Medicine; Immunization; Female; Patient Safety

Background We describe the early experiences of adults with systemic rheumatic disease who received COVID-19 vaccine. Methods From 2 April to 30 2021, we conducted an online, international survey vaccination. collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around time vaccination, adverse events after Results analysed 2860 diseases vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) others (1.2%). The most common was rheumatoid arthritis (42.3%), 81.2% respondents a DMARD. majority (81.9%) reported communicating clinicians Most (66.9%) willing temporarily discontinue DMARDs improve vaccine efficacy, although many (44.3%) concerned flares. After fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) fever/chills (19.9%). Rheumatic flares that required medication changes occurred in 4.6%. Conclusion Among typical those general population. patients efficacy. relatively low frequency flare requiring medications reassuring.